(Total Views: 893)
Posted On: 07/29/2020 9:34:06 PM
Post# of 153937
A quick leap of logic...
If an institutional investor is willing to lend that much money at double our share price, they must like what they see. And what is it they see that is different from a week or two ago?
Results.
Something must have been shared with them because they aren’t investing that kind of money on a wing and a prayer. So, if they got a sneak peek at the (or some of the) results...what are the chances that the interested big pharma companies have also seen the same data?
So if the data is coming out behind closed doors, and it’s good, we could very well see some licensing/partnering deals announced at any minute too.
While it remains to be seen just how positive the data will be, I think this deal gives us a big reason to believe that at least some of the efficacy data is very good. I can’t wait for tomorrow to find out more!
If an institutional investor is willing to lend that much money at double our share price, they must like what they see. And what is it they see that is different from a week or two ago?
Results.
Something must have been shared with them because they aren’t investing that kind of money on a wing and a prayer. So, if they got a sneak peek at the (or some of the) results...what are the chances that the interested big pharma companies have also seen the same data?
So if the data is coming out behind closed doors, and it’s good, we could very well see some licensing/partnering deals announced at any minute too.
While it remains to be seen just how positive the data will be, I think this deal gives us a big reason to believe that at least some of the efficacy data is very good. I can’t wait for tomorrow to find out more!
(5)
(0)
